DCM
BCAX

DAFNA Capital Management’s Bicara Therapeutics BCAX Stock Holding History

DAFNA Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.46M Sell
284,955
-136,778
-32% -$3.05M 1.61% 17
2026
Q1 		$8.39M Buy
421,733
+160,150
+61% +$2.76M 1.91% 15
2025
Q4 		$4.4M Sell
261,583
-55,418
-17% -$946K 1.02% 24
2025
Q3 		$5.01M Hold
317,001
– – 1.24% 18
2025
Q2 		$2.94M Buy
317,001
+105,000
+50% +$1.25M 0.81% 32
2025
Q1 		$2.76M Buy
212,001
+106,501
+101% +$1.41M 0.78% 33
2024
Q4 		$1.84M Buy
+105,500
New +$2.2M 0.47% 40

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DAFNA Capital Management's BCAX Position: Q2 2026 in Review

DAFNA Capital Management reduced its Bicara Therapeutics (BCAX) stake by 32% in Q2 2026, selling an estimated $3.05M and leaving 284,955 shares worth $8.46M. The position accounts for 1.61% of the portfolio, ranked #17.

DAFNA Capital Management first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • DAFNA Capital Management held 284,955 shares of Bicara Therapeutics worth $8.46M as of Q2 2026.
  • DAFNA Capital Management sold 136,778 Bicara Therapeutics shares in Q2 2026, an estimated $3.05M.
  • Bicara Therapeutics made up 1.61% of DAFNA Capital Management's portfolio in Q2 2026, its #17 holding.
  • DAFNA Capital Management first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.